Geneva, 21 November 2019 – Gavi, the Vaccine Alliance has congratulated the Global Polio Eradication Initiative (GPEI) for raising vital funds towards its Polio Endgame Strategy 2019-2023 at a pledging event in Abu Dhabi, United Arab Emirates.

“I want to offer my congratulations to the Global Polio Eradication Initiative on receiving these critical political and financial commitments,” said Dr Seth Berkley, CEO of Gavi. “The world has made tremendous progress on polio in little under three decades, thanks in large part to the work led by GPEI and national governments. It is important that we have sufficient resources to ensure that we do not backslide and lose that progress. Polio will remain a threat until every child is protected against this crippling disease.”

In March 2019, the CEO of Gavi became a member of GPEI’s Polio Oversight Board, and in October 2019, the Alliance joined WHO, Rotary International, the United States Centers for Disease Control and Prevention (CDC), UNICEF, and the Bill & Melinda Gates Foundation as an official core partner. Gavi’s work strengthening routine immunisation programmes will be critical in the ongoing fight against polio.

With Gavi and GPEI support, more than 70 Gavi-supported countries successfully introduced Inactivated Polio Vaccine (IPV) into their national immunisation programmes between 2014 and early 2019 – the fastest ever global introduction of a new vaccine, and a critical milestone for achieving and sustaining a polio-free world.

Investing in IPV will continue to be a part of Gavi’s core strategy for 2019-2020, and subject to funding, the Alliance plans to invest US$ 800 million to maintain IPV in national routine immunisation programmes and support ramping up to a two-dose schedule. Gavi’s own replenishment process for the 2021-25 period will culminate in a special event hosted by the UK government in June 2020.

Polio is highly contagious, and without a concerted push towards global eradication, the world could very easily backslide. The number of polio cases have fallen by more than 99% between 1988 and 2018. However, studies have shown that current rates of routine immunisation coverage are not high enough to adopt a control strategy that allows for a threshold of polio cases a year. Within a decade, a resurgence of the disease would probably paralyse more than 200,000 children a year.

When taking into account treatment and operational costs as well as losses in productivity, eradication is the most cost-effective approach as compared to the alternatives. Economic modelling has found that the eradication of polio would save at least US$ 40–50 billion by 2035, mostly in low-income countries.

Notes to editors

About Gavi, the Vaccine Alliance

Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world’s children against some of the world’s deadliest diseases. Since its inception in 2000, Gavi has helped to immunise a whole generation – over 760 million children – and prevented more than 13 million deaths, helping to halve child mortality in 73 developing countries. Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningitis and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation and reaching the unvaccinated children still being left behind, employing innovative finance and the latest technology – from drones to biometrics – to save millions more lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency. Learn more at and connect with us on Facebook and Twitter.

The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation and other private sector partners. View the full list of donor governments and other leading organizations that fund Gavi’s work here.

Subscribe to our newsletter